

S1 Table. Preferred reporting items for systematic reviews and meta-analyses checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4-5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	6
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	7
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7

Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	8
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	8

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	8
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	8
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	9
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	9
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	9
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	9
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	12
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	12
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	13
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	13
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	16

Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	17
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	17

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

S2 Table. Search strategy in Medline (Pubmed)

Search	Virus
#1	“HRSV” OR “RSV” OR “human respiratory syncytial virus”OR “respiratory syncytial virus” OR “HRSV-A” OR “HRSV-B” OR “HMPV” OR “MPV” OR “human metapneumovirus”OR “metapneumovirus” OR “HMPV-A” OR “HMPV-B” OR “HAdV” OR “AdV” OR “Adenovirus” OR “Adenovirus Infections, Human” OR “Human adenovirus” OR “HADV-A” OR “HADV-B” OR “HADV-C” OR “HADV-D” OR “HADV-E” OR “HADV-F” OR “HADV-G” OR “HBoV” OR “BoV” OR “Bocavirus” OR “Bocavirus Infections, Human” OR “Human Bocavirus” OR “HCoV” OR “CoV” OR “Coronavirus” OR “Coronavirus Infections, Human” OR “Human Coronavirus” OR “229E” OR “OC43” OR “NL63” OR “HKU1” OR “HCoV-229E” OR “HCoV-OC43” OR “HCoV-NL63” OR “HCoV-HKU1” OR “HPIV” OR “PIV” OR “Parainfluenzavirus” OR “Parainfluenzavirus Infections, Human” OR “Human Parainfluenzavirus” OR “PIV-1” OR “PIV-2” OR “PIV-3” OR “PIV-4” OR “HPIV-1” OR “HPIV-2” OR “HPIV-3” OR “HPIV-4” OR “HEV” OR “EV” OR “Enterovirus” OR “Enterovirus Infections, Human” OR “Human Enterovirus” OR “HRV” OR “RV” OR “Rhinovirus” OR “Rhinoviruses” OR “Rhinovirus Infections, Human” OR “Human Rhinovirus” OR “RV-A” OR “RV-B” OR “RV-C” OR “Influenza” OR “Inf” OR “Influenza virus” OR “Influenza, Human” OR “Influenza-A virus” OR “Influenza-B virus” OR “Influenza-C virus”
#2	bronchiolitis
#3	#1 AND #2

S3 Table. Items for risk of bias assessment

Hoy et al. tool for cross sectional studies	Yes (1)/No (0)
External validity	
1. Was the study's target population a close representation of the national population in relation to relevant variables?	1
2. Was the sampling frame a true or close representation of the bronchiolitis population?	1
3. Was some form of random selection used to select the sample, OR was a census undertaken?	1
4. Was the likelihood of non response bias minimal?	1
Internal validity	
5. Were data collected directly from the subjects (as opposed to a proxy)?	1
6. Was an acceptable bronchiolitis case definition used in the study?	1
7. Was the study viral detection assay shown to have validity and reliability?	1
8. Was the same mode type of sample collected for all subjects?	1
9. Was the length of the shortest prevalence period for the parameter of interest appropriate?	1
10. Were the numerator(s) and denominator(s) for the parameter of interest appropriate?	1
Total score	10
Interpretation of the risk of bias tool	
<ul style="list-style-type: none"> • 7-10: Low risk of bias • 4-6: Moderate risk of bias • 0-3: High risk of bias 	

S4 Table. Main reasons of exclusion of eligible studies

N°	Name, Year	Title	Reason of exclusion
1	Akhras, 2010	Human metapneumovirus and respiratory syncytial virus: subtle differences but comparable severity	No molecular assays used
2	Alonso, 2007	Bronchiolitis due to respiratory syncytial virus in hospitalized children: a study of seasonal rhythm.	Only positive samples included
3	Al-Shawwa, 2007	Clinical and therapeutic variables influencing hospitalisation for bronchiolitis in a community-based paediatric group practice	No molecular assays used
4	Al-Shehri, 2005	Bronchiolitis in Abha, Southwest Saudi Arabia: viral etiology and predictors for hospital admission.	No molecular assays used
5	Alvarez, 2013	Epidemiological and genetic characteristics associated with the severity of acute viral bronchiolitis by respiratory syncytial virus.	Systematic review
6	Amér, 2009	[Not only RSV can cause bronchiolitis in small children	Full text not found
7	Bakalovic, 2015	Epidemiological Features of Bronchiolitis in the Pediatric Clinic of Clinical center of Sarajevo University.	Data on detection assay not reported
8	Barr, 2018	Change in viral bronchiolitis management in hospitals in the UK after the publication of NICE guideline.	No data on viral etiology searched
9	Bashir, 2017	Respiratory syncytial virus and influenza are the key viral pathogens in children <2 years hospitalized with bronchiolitis and pneumonia in Islamabad Pakistan.	Not possible to extract data on viral etiology searched
10	Bauert, 2019	Rhinovirus Species in Children With Severe Bronchiolitis: Multicenter Cohort Studies in the United States and Finland	Duplicates
11	Bennett, 2018	Population-based trends and underlying risk factors for infant respiratory syncytial virus and bronchiolitis hospitalizations.	Inappropriate study population
12	Berezin, 2006	Rhinovirus and bronchiolitis.	Comments
13	Bilavsky, 2010	Respiratory syncytial virus-positive bronchiolitis in hospitalized infants is associated with thrombocytosis.	No molecular assays used
14	Bochkov, 2020	A 14-year Prospective Study of Human Coronavirus Infections in Hospitalized Children: Comparison With Other Respiratory Viruses.	Inappropriate study population
15	Bouscambert-Duchamp, 2005	Detection of human metapneumovirus RNA sequences in nasopharyngeal aspirates of young French children with acute bronchiolitis by real-time reverse transcriptase PCR and phylogenetic analysis.	Duplicate of Janahi, 2017
16	Boyce, 2004	Incidence of bronchiolitis-associated hospitalization among children in Olmsted County, Minnesota.	Comments
17	Boyce, 2016	More on Viral Bronchiolitis in Children.	Comments

18	Bradley, 2005	Severity of respiratory syncytial virus bronchiolitis is affected by cigarette smoke exposure and atopy.	Only positive samples included
19	Brini, 2018	Temporal and climate characteristics of respiratory syncytial virus bronchiolitis in neonates and children in Sousse, Tunisia, during a 13-year surveillance	No molecular assays used
20	Brini, 2020	Temporal and climate characteristics of respiratory syncytial virus bronchiolitis in neonates and children in Sousse, Tunisia, during a 13-year surveillance.	Inappropriate detection assay
21	Calvo, 2015	Respiratory Syncytial Virus Coinfections With Rhinovirus and Human Bocavirus in Hospitalized Children	> 2 years
22	Cantani, 1999	Bronchiolitis in infants.	No data on viral etiology searched
23	Causse, 2007	Preliminary evaluation of a multiplex reverse transcription-PCR assay combined with a new DNA chip hybridization assay for detecting respiratory syncytial virus	> 2 years
24	Cavallin, 2013	Infection with multiple viruses is not associated with increased disease severity in children with bronchiolitis.	Comments
25	Centers for Disease Control and Prevention (CDC), 2003	Bronchiolitis-associated outpatient visits and hospitalizations among American Indian and Alaska Native children--United States, 1990-2000.	Report
26	Chan, 2002	Risk factors for hypoxemia and respiratory failure in respiratory syncytial virus bronchiolitis.	Only positive samples included
27	Chee, 2010	Emergency Department Septic Screening in Respiratory Syncytial Virus (RSV) and Non-RSV Bronchiolitis.	No molecular assays used
28	Chen, 2004	[Clinical characteristics of bronchiolitis caused by human metapneumovirus in infants]	Full text not found
29	Chen, 2014	Viral etiology of bronchiolitis among pediatric inpatients in northern Taiwan with emphasis on newly identified respiratory viruses.	Combination of multiple assays for detection
30	Ciarlito, 2019	Respiratory Syncytial Virus A and B: three bronchiolitis seasons in a third level hospital in Italy.	Inappropriate study population
31	Connors, 2016	Viral Bronchiolitis in Children.	Comments
32	Coskun, 2017	Risk factors for intensive care need in children with bronchiolitis: A case-control study.	Data on detection assay not reported
33	Côté, 2003	Comparative evaluation of real-time PCR assays for detection of the human metapneumovirus	No data on viral etiology searched
34	CRONE, 1964	SEROLOGICAL EVIDENCE OF INFECTION BY RESPIRATORY SYNCYTIAL VIRUS IN OUTBREAK OF ACUTE BRONCHIOLITIS	No molecular assays used
35	Cubie, 1992	Detection of respiratory syncytial virus in acute bronchiolitis in infants	Not possible to extract data on viral etiology searched

36	Dagan, 1993	Hospitalization of Jewish and Bedouin infants in southern Israel for bronchiolitis caused by respiratory syncytial virus	No molecular assays used
37	Davies, 2017	A systematic review of the psychometric properties of bronchiolitis assessment tools.	Systematic review
38	DeVincenzo, 2016	Viral Bronchiolitis in Children.	Comments
39	Dotan, 2013	Hospitalization for respiratory syncytial virus bronchiolitis and disease severity in twins.	Only positive samples included
40	Duttweiler, 2004	Pulmonary and systemic bacterial co-infections in severe RSV bronchiolitis.	Only positive samples included
41	Eidelman, 2009	The burden of respiratory syncytial virus bronchiolitis on a pediatric inpatient service.	No molecular assays used
42	Erculj, 2018	PM10 exposure is associated with increased hospitalizations for respiratory syncytial virus bronchiolitis among infants in Lombardy, Italy.	Only positive samples included
43	Erez, 2012	[Prevalence of H1N1 A influenza virus infection among hospitalized patients with bronchiolitis twelve months old and younger]	Full text not found
44	Eugene-Ruellan, 1998	Detection of respiratory syncytial virus A and B and parainfluenzavirus 3 sequences in respiratory tracts of infants by a single PCR with primers targeted to the L-polymerase gene and differential hybridization	Age range not reported
45	FANDRE, 1964	[EPIDEMIC OF ACUTE BRONCHIOLITIS IN INFANTS. ISOLATION OF A RESPIRATORY SYNEYTIAL VIRUS]	Full text not found
46	Fauroux, 2017	The Burden and Long-term Respiratory Morbidity Associated with Respiratory Syncytial Virus Infection in Early Childhood.	Systematic review
47	Fedele, 2018	Analysis of the immune response in infants hospitalized with viral bronchiolitis shows different Th1/Th2 profiles associated with respiratory syncytial virus and human rhinovirus.	Inappropriate study population
48	Ferronato, 2012	Etiological diagnosis reduces the use of antibiotics in infants with bronchiolitis.	No molecular assays used
49	Fjaerli, 2004	Hospitalisations for respiratory syncytial virus bronchiolitis in Akershus, Norway, 1993-2000: a population-based retrospective study.	No molecular assays used
50	Flaherman, 2010	Respiratory syncytial virus testing during bronchiolitis episodes of care in an integrated health care delivery system: a retrospective cohort study.	No molecular assays used
51	Flamant, 2005	Severe respiratory syncytial virus bronchiolitis in children: from short mechanical ventilation to extracorporeal membrane oxygenation.	No molecular assays used
52	Flores, 2004	Bronchiolitis caused by respiratory syncytial virus in an area of portugal: epidemiology, clinical features, and risk factors.	> 2 years
53	Fodha, 2007	Respiratory syncytial virus infections in hospitalized infants: association between viral load, virus subgroup, and disease severity	Only positive samples included

54	Foley, 2018	Respiratory health inequality starts early: The impact of social determinants on the aetiology and severity of bronchiolitis in infancy.	No molecular assays used
55	Foo, 1991	Severe bronchiolitis in children	Full text not found
56	FORBES, 1961	Epidemic bronchiolitis caused by a respiratory syncytial virus: clinical aspects	Conference abstract
57	Fretzayas, 2017	Etiology and clinical features of viral bronchiolitis in infancy.	Review
58	Freymouth, 2003	Presence of the new human metapneumovirus in French children with bronchiolitis.	Age range not reported
59	Fujiogi, 2020	Association of rhinovirus species with nasopharyngeal metabolome in bronchiolitis infants: A multicenter study.	Duplicates
60	Ganu, 2012	Increase in use of non-invasive ventilation for infants with severe bronchiolitis is associated with decline in intubation rates over a decade	Data on detection assay not reported
61	Garcia, 2010	Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis.	No molecular assays used
62	Garcia-Marcos, 2014	Pediatricians' attitudes and costs of bronchiolitis in the emergency department: a prospective multicentre study.	No data on viral etiology searched
63	Ghazaly, 2018	Characteristics of children admitted to intensive care with acute bronchiolitis.	Combination of multiple assays for detection
64	Ghazaly, 2018	Characteristics of children admitted to intensive care with acute bronchiolitis.	Inappropriate detection assay
65	Giordano, 2018	Respiratory syncytial virus bronchiolitis and hypertransaminasemia.	Case report
66	Gold, 2006	[Respiratory syncytial virus bronchiolitis: severe respiratory forms in hospitalized infants]	Review
67	González Martínez, 2013	[Clinical impact of introducing ventilation with high flow oxygen in the treatment of bronchiolitis in a paediatric ward]	No molecular assays used
68	Goto-Sugai, 2010	Genotyping and phylogenetic analysis of the major genes in respiratory syncytial virus isolated from infants with bronchiolitis.	Only positive samples included
69	Greensill, 2003	Human metapneumovirus in severe respiratory syncytial virus bronchiolitis.	Age range not reported
70	Grimaldi, 2002	[Prospective regional study of an epidemic of respiratory syncytial virus]	Only positive samples included
71	Grimwood, 2008	Risk factors for respiratory syncytial virus bronchiolitis hospital admission in New Zealand.	Combination of multiple assays for detection
72	Grubbauer, 1989	[Respiratory insufficiency in acute bronchiolitis in infancy]	Full text not found
73	Haque, 2012	Bronchiolitis outbreak caused by respiratory syncytial virus in southwest Bangladesh, 2010.	Outbreak
74	Hasegawa, 2014	Multicenter study of viral etiology and relapse in hospitalized children with bronchiolitis.	Duplicate of Dumas, 2016
75	Hasegawa, 2014	Infectious pathogens and bronchiolitis outcomes.	Review
76	Hasegawa, 2015	Risk factors for requiring intensive care among children admitted to ward with bronchiolitis.	Duplicate of Dumas, 2016

77	Hasegawa, 2015	Respiratory syncytial virus genomic load and disease severity among children hospitalized with bronchiolitis: multicenter cohort studies in the United States and Finland.	Duplicate of Dumas, 2016
78	Hasegawa, 2018	Rhinovirus Species in Children with Severe Bronchiolitis: Multicenter Cohort Studies in the US and Finland.	Duplicate of Dumas, 2016
79	Hasegawa, 2019	Respiratory Virus Epidemiology Among US Infants With Severe Bronchiolitis: Analysis of 2 Multicenter, Multiyear Cohort Studies.	Duplicates
80	Hasegawa, 2019	Association of Rhinovirus C Bronchiolitis and Immunoglobulin E Sensitization During Infancy With Development of Recurrent Wheeze.	Duplicates
81	Heinonen, 2018	Transient Tachypnea of the Newborn is Associated with an Increased Risk of Hospitalization Due to RSV Bronchiolitis.	Data on detection assay not reported
82	Hendaus, 2014	Does cesarean section pose a risk of respiratory syncytial virus bronchiolitis in infants and children?	> 2 years
83	Henderson, 1979	The etiologic and epidemiologic spectrum of bronchiolitis in pediatric practice	No molecular assays used
84	Hervas, 2012	Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis.	No molecular assays used
85	Houben, 2011	Clinical prediction rule for RSV bronchiolitis in healthy newborns: prognostic birth cohort study	Not bronchiolitis
86	Howidi, 2007	The severity of respiratory syncytial virus bronchiolitis in young infants in the United Arab Emirates.	No molecular assays used
87	Huguenin, 2012	Broad respiratory virus detection in infants hospitalized for bronchiolitis by use of a multiplex RT-PCR DNA microarray system.	Age range not reported
88	Hyvarinen, 2011	Outcome after bronchiolitis depends on disease definition.	Only positive samples included
89	Jacques, 2006	Association of respiratory picornaviruses with acute bronchiolitis in French infants.	Duplicate of Janahi, 2017
90	Jacques, 2008	Human Bocavirus quantitative DNA detection in French children hospitalized for acute bronchiolitis.	> 2 years
91	Jartti, 2015	Rhinovirus-induced bronchiolitis: Lack of association between virus genomic load and short-term outcomes	Duplicate of Dumas, 2016
92	Jelić, 1990	[A bronchiolitis epidemic caused by respiratory syncytial viruses]	Full text not found
93	Jevsnik, 2016	The Role of Human Coronaviruses in Children Hospitalized for Acute Bronchiolitis, Acute Gastroenteritis, and Febrile Seizures: A 2-Year Prospective Study.	> 2 years
94	Jhavar, 2003	Severe bronchiolitis in children.	Review
95	Kabir, 2003	Evaluation of hospitalized infants and young children with bronchiolitis-a multi centre study.	Full text not found
96	Karr, 2009	Infant exposure to fine particulate matter and traffic and risk of hospitalization for RSV	No data on viral etiology searched

		bronchiolitis in a region with lower ambient air pollution.	
97	Kassis, 2009	[The burden and outcomes of acute bronchiolitis among young children hospitalized in Israel]	Full text not found
98	Kemper, 2005	Hospital readmission for bronchiolitis.	No data on viral etiology searched
99	Korppi, 2012	Upper age limit for bronchiolitis: 12 months or 6 months?	Comments
100	Korppi, 2015	Bronchiolitis: the disease of <6-month-old, <12-month-old or <24-month-old infants.	Comments
101	Kua, 2017	Systematic Review and Meta-Analysis of the Efficacy and Safety of Combined Epinephrine and Corticosteroid Therapy for Acute Bronchiolitis in Infants.	Systematic review
102	Laham, 2017	Clinical Profiles of Respiratory Syncytial Virus Subtypes A AND B Among Children Hospitalized with Bronchiolitis.	Duplicate of Dumas, 2016
103	Lanari, 2015	Prenatal tobacco smoke exposure increases hospitalizations for bronchiolitis in infants.	No data on viral etiology searched
104	Lanari, 2015	Risk factors for bronchiolitis hospitalization during the first year of life in a multicenter Italian birth cohort.	No data on viral etiology searched
105	Lanari, 2016	Exposure to vehicular traffic is associated to a higher risk of hospitalization for bronchiolitis during the first year of life.	Full text not found
106	Legg, 2005	Frequency of detection of picornaviruses and seven other respiratory pathogens in infants	Not bronchiolitis
107	Lin, 2009	[Detection of human metapneumovirus and human bocavirus in children with bronchiolitis in east Guangdong area]	Full text not found
108	López-Huertas, 2005	Two RT-PCR based assays to detect human metapneumovirus in nasopharyngeal aspirates	Not bronchiolitis
109	Lowther, 2000	Bronchiolitis-associated hospitalizations among American Indian and Alaska Native children.	No data on viral etiology searched
110	Luo, 2014	A systematic review of predictive modeling for bronchiolitis.	Systematic review
111	Mação, 2011	[Acute bronchiolitis: a prospective study]	Data on detection assay not reported
112	Macfarlane, 2005	RSV testing in bronchiolitis: which nasal sampling method is best?	No molecular assays used
113	Mandal, 2017	Bronchiolitis: Comparative Study between Respiratory Syncytial Virus	Comments
114	Mandal, 2017	Bronchiolitis: Comparative Study between Respiratory Syncytial Virus (RSV) and Non RSV Aetiology.	Comments
115	Mansbach, 2008	Prospective multicenter study of the viral etiology of bronchiolitis in the emergency department	Not possible to extract data on viral etiology searched
116	Mansbach, 2012	Prospective multicenter study of viral etiology and hospital length of stay in children with severe bronchiolitis	Duplicate of Dumas, 2016
117	Mansbach, 2016	Children Hospitalized with Rhinovirus Bronchiolitis Have Asthma-Like Characteristics.	Duplicate of Dumas, 2016

118	Mansbach, 2016	Respiratory syncytial virus and rhinovirus severe bronchiolitis are associated with distinct nasopharyngeal microbiota.	Comments
119	Mansbach, 2018	Haemophilus-dominant nasopharyngeal microbiota is associated with delayed clearance of respiratory syncytial virus in infants hospitalized for bronchiolitis	Duplicate of Mansbach, 2016
120	Mansbach, 2019	Association between rhinovirus species and nasopharyngeal microbiota in infants with severe bronchiolitis.	Duplicates
121	Mansbach, 2020	Detection of respiratory syncytial virus or rhinovirus weeks after hospitalization for bronchiolitis and the risk of recurrent wheezing.	Duplicates
122	Marguet, 2009	In very young infants severity of acute bronchiolitis depends on carried viruses.	Combination of multiple assays for detection
123	McCuskee, 2014	Bronchiolitis and pneumonia requiring hospitalization in young first nations children in Northern Ontario, Canada.	Not possible to extract data on viral etiology searched
124	McErlean, 2007	Characterisation of a newly identified human rhinovirus, HRV-QPM, discovered in infants with bronchiolitis.	> 2 years
125	McNally, 2014	Vitamin D receptor (VDR) polymorphisms and severe RSV bronchiolitis: a systematic review and meta-analysis.	Systematic review
126	McNamara, 2007	Impact of human metapneumovirus and respiratory syncytial virus co-infection in severe bronchiolitis.	Age range not reported
127	Meissner, 2016	Viral Bronchiolitis in Children.	Comments
128	Meissner, 2016	More on Viral Bronchiolitis in Children.	Comments
129	Meissner, 2016	Viral Bronchiolitis in Children.	Review
130	Mikalsen, 2012	The outcome after severe bronchiolitis is related to gender and virus.	Only positive samples included
131	Miron, 2010	Sole pathogen in acute bronchiolitis: is there a role for other organisms apart from respiratory syncytial virus?	Combination of multiple assays for detection
132	Molinari Such, 2005	Respiratory syncytial virus-related bronchiolitis in Puerto Rico.	Only positive samples included
133	Munoz-Quiles, 2016	Population-based Analysis of Bronchiolitis Epidemiology in Valencia, Spain.	No data on viral etiology searched
134	Murray, 2014	Risk factors for hospital admission with RSV bronchiolitis in England: a population-based birth cohort study.	No data on viral etiology searched
135	Naja, 2019	Bronchiolitis Admissions in a Lebanese Tertiary Medical Center: A 10 Years' Experience.	Inappropriate study population
136	Najioullah, 2020	Seasonality and coinfection of bronchiolitis: epidemiological specificity and consequences in terms of prophylaxis in tropical climate.	Inappropriate detection assay
137	Narbona-Lopez, 2018	Prevention of syncytial respiratory virus infection with palivizumab: descriptive and comparative analysis after 12 years of use.	Full text not found

138	Nenna, 2017	Modifiable risk factors associated with bronchiolitis.	No data on viral etiology searched
139	Neves Barreira, 2001	[Relationship between respiratory syncytial virus subtype and clinical severity in bronchiolitis]	Full text not found
140	Nicolai, 2013	Viral bronchiolitis in children: a common condition with few therapeutic options.	Review
141	O'Connor, 2013	The changing epidemiology of the bronchiolitis epidemic in Tallaght Hospital.	Full text not found
142	Oliveira-Santos, 2016	Influence of meteorological conditions on RSV infection in Portugal	No molecular assays used
143	Ong, 2001	A comparison of nested polymerase chain reaction and immunofluorescence for the diagnosis of respiratory infections in children with bronchiolitis, and the implications for a cohorting strategy	No molecular assays used
144	Ozkaya-Parlakay, 2019	Viral Etiology of Bronchiolitis Among Pediatric Patients.	Inappropriate study design
145	Papadopoulos, 2004	Does respiratory syncytial virus subtype influence the severity of acute bronchiolitis in hospitalized infants?	Only positive samples included
146	Paranhos-Baccalà, 2008	Mixed respiratory virus infections	Review
147	Paul, 2017	Respiratory-syncytial-virus- and rhinovirus-related bronchiolitis in children aged <2 years in an English district general hospital.	Not possible to extract data on viral etiology searched
148	Perrin, 1986	[Predictive indicators of the severity of bronchiolitis caused by respiratory syncytial virus in infants]	Full text not found
149	Pichler, 2000	Severe adenovirus bronchiolitis in children.	Case report
150	Pickles, 2015	Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis.	Review
151	Piedimonte, 2014	Respiratory syncytial virus infection and bronchiolitis.	Review
152	Prais, 2003	Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use.	No molecular assays used
153	Pruikkonen, 2014	Infants under 6 months with bronchiolitis are most likely to need major medical interventions in the 5 days after onset.	No molecular assays used
154	Rahbarimanesh, 2018	Viral Aetiology of Bronchiolitis in Hospitalised Children in a Tertiary Center in Tehran.	No molecular assays used
155	Rahbarimanesh, 2018	Viral Aetiology of Bronchiolitis in Hospitalised Children in a Tertiary Center in Tehran.	Inappropriate detection assay
156	Ralston, 2009	Incidence of apnea in infants hospitalized with respiratory syncytial virus bronchiolitis: a systematic review.	Systematic review
157	Ramagopal, 2016	Demographic, Clinical and Hematological Profile of Children with Bronchiolitis: A Comparative Study between Respiratory Syncytial Virus [RSV] and [Non RSV] Groups.	> 2 years
158	Rivera-Sepulveda, 2017	Epidemiology of bronchiolitis: a description of emergency department visits and hospitalizations in Puerto Rico, 2010-2014.	No data on viral etiology searched

159	Rodl, 2012	Prospective evaluation of clinical scoring systems in infants with bronchiolitis admitted to the intensive care unit.	No data on viral etiology searched
160	Rodriguez-Fernandez, 2017	Respiratory Syncytial Virus Genotypes, Host Immune Profiles, and Disease Severity in Young Children Hospitalized With Bronchiolitis.	Only positive samples included
161	Rodriguez-Martinez, 2018	Predictors of prolonged length of hospital stay for infants with bronchiolitis.	No molecular assays used
162	Rossi, 2016	Viral Bronchiolitis in Children.	Comments
163	Ryu, 2015	Etiology and Outcome of Diffuse Acute Infectious Bronchiolitis in Adults.	Combination of multiple assays for detection
164	Saijo, 1994	The role of respiratory syncytial virus in acute bronchiolitis in small children in northern Japan	No molecular assays used
165	Sala, 2015	Factors associated with disease severity in children with bronchiolitis.	No data on viral etiology searched
166	Sanchez-Luna, 2016	Trends in respiratory syncytial virus bronchiolitis hospitalizations in children less than 1 year: 2004-2012.	No data on viral etiology searched
167	Sarkar, 2018	Comparative Study between Noninvasive Continuous Positive Airway Pressure and Hot Humidified High-flow Nasal Cannulae as a Mode of Respiratory Support in Infants with Acute Bronchiolitis in Pediatric Intensive Care Unit of a Tertiary Care Hospital.	No data on viral etiology searched
168	Scagnolari, 2012	Evaluation of viral load in infants hospitalized with bronchiolitis caused by respiratory syncytial virus.	Only positive samples included
169	Schaller, 2017	Bronchiolitis in Infants and Children.	Review
170	Semple, 2005	Dual infection of infants by human metapneumovirus and human respiratory syncytial virus is strongly associated with severe bronchiolitis.	Age range not reported
171	Semple, 2011	Household tobacco smoke and admission weight predict severe bronchiolitis in infants independent of deprivation: prospective cohort study.	No molecular assays used
172	Shadman, 2012	50 years ago in The Journal of Pediatrics: Observations on the etiology of acute bronchiolitis in infants.	Review
173	Shang, 2014	Elective cesarean delivery as a predisposing factor of respiratory syncytial virus bronchiolitis in children	> 2 years
174	Shay, 2001	Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997.	No data on viral etiology searched
175	Shmueli, 2017	Real-life comparison of three general paediatric wards showed similar outcomes for children with bronchiolitis despite different treatment regimens.	No molecular assays used
176	Simon, 2007	Detection of bocavirus DNA in nasopharyngeal aspirates of a child with bronchiolitis.	Case report
177	Sloan, 2013	Spatiotemporal patterns of infant bronchiolitis in a Tennessee Medicaid population.	No data on viral etiology searched
178	Smyth, 2002	Respiratory syncytial virus bronchiolitis: disease severity, interleukin-8, and virus genotype.	Only positive samples included

179	Soo, 2017	Pulmonary hemorrhage as a complication of Respiratory Syncytial Virus (RSV) bronchiolitis.	Case report
180	Stempel, 2009	Multiple viral respiratory pathogens in children with bronchiolitis.	No data on viral etiology searched
181	Stevenson, 2016	Prenatal Versus Postnatal Tobacco Smoke Exposure and Intensive Care Use in Children Hospitalized With Bronchiolitis.	Duplicate of Dumas, 2016
182	Stewart, 2019	Association of respiratory viruses with serum metabolome in infants with severe bronchiolitis.	Duplicates
183	Stollar, 2014	Virologic testing in bronchiolitis: does it change management decisions and predict outcomes?	Combination of multiple assays for detection
184	Tecu, 2006	The viral bronchiolites diagnosis in children by PCR multiplex	Full text not found
185	Tecu, 2012	The adenoviral infections in children admitted to hospital with pneumonia, acute bronchiolitis or respiratory viral infections.	Full text not found
186	Toivonen, 2019	Association between rhinovirus species and nasopharyngeal microbiota in infants with severe bronchiolitis	Duplicate of Mansbach, 2016
187	Tortora, 2015	Adenovirus species C detection in children under four years of age with acute bronchiolitis or recurrent wheezing.	> 2 years
188	Toyoshima, 2011	Bronchiolitis caused by pandemic influenza A (H1N1) 2009.	Case report
189	Tsolia, 2003	Epidemiology of respiratory syncytial virus bronchiolitis in hospitalized infants in Greece.	No molecular assays used
190	Tumba, 2020	Temporal trend of hospitalizations for acute bronchiolitis in infants under one year of age in Brazil between 2008 and 2015.	No data on respiratory viruses prevalence
191	Valdivia, 1997	Analysis of respiratory syncytial virus in clinical samples by reverse transcriptase-polymerase chain reaction restriction mapping	Age range not reported
192	Van Rostenberghe, 2006	RSV and bronchiolitis.	Comments
193	van Woensel, 2002	Bronchiolitis hospitalisations in the Netherlands from 1991 to 1999.	No data on viral etiology searched
194	Vicente, 1978	[Etiologic importance of the respiratory syncytial virus in bronchiolitis]	Full text not found
195	Wall, 2016	Viral Bronchiolitis in Children.	Comments
196	Werno, 2004	Human metapneumovirus in children with bronchiolitis or pneumonia in New Zealand.	> 2 years
197	Willson, 2003	Complications in infants hospitalized for bronchiolitis or respiratory syncytial virus pneumonia.	Data on detection assay not reported
198	Wolfler, 2018	The infant with severe bronchiolitis: from HFNC to CPAP and mechanical ventilation.	Review
199	Wright, 2002	Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus.	Only positive samples included
200	Yitshak-Sade, 2017	Air Pollution and Hospitalization for Bronchiolitis among Young Children.	No data on viral etiology searched

201	Yi-Wei, 2018	A molecular epidemiological study of respiratory syncytial virus circulating in southern Zhejiang Province, China, from 2009 to 2014.	Inappropriate detection assay
202	Yorita, 2007	Severe bronchiolitis and respiratory syncytial virus among young children in Hawaii.	Data on detection assay not reported
203	Zhang, 2017	[Molecular biological and clinical characteristics of respiratory syncytial virus in children with bronchiolitis]	Full text not found

SS Table. Individual characteristics of included studies

Name, Year	Male (%)	Age	Age Range	Period	Design	Sampling	Timing	Country	Language	Bias	Setting	Case definition	Sample type	Virus Searched	Viral diagnostic method
Chen, 2014	97	1-6 months (n = 259)	< 1 Year	Oct 2011-May 2012	Cross-sectional	Consecutive	Prospectively	France	English	Medium risk	Outpatient	Brochialis was diagnosed by the presence of a recent history of acute respiratory tract infection followed by onset of respiratory distress with cough, tachypnea, retractions and diffuse crackles, or wheezing on auscultation, in accordance with the national recommendations for the diagnosis and management of acute bronchiolitis (McConnochie et al. 2009)	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	Real-time PCR
Antoni, 2010	Not reported	Not reported	< 1 Year	Nov 2002-Aug 2008	Cross-sectional	Consecutive	Prospectively	Peru	English	Medium risk	Outpatient	Brochialis was diagnosed by the presence of a recent history of acute respiratory tract infection followed by onset of respiratory distress with cough, tachypnea, retractions and diffuse crackles, or wheezing on auscultation, in accordance with the national recommendations for the diagnosis and management of acute bronchiolitis (McConnochie et al. 2009)	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	Real-time PCR
Almohdhi, 2010	Not reported	Not reported	< 1 Year	July 2009	Cross-sectional	Consecutive	Prospectively	Iran	Non-English	Medium risk	Outpatient	Brochialis was diagnosed by the presence of a recent history of acute respiratory tract infection followed by onset of respiratory distress with cough, tachypnea, retractions and diffuse crackles, or wheezing on auscultation, in accordance with the national recommendations for the diagnosis and management of acute bronchiolitis (McConnochie et al. 2009)	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	Real-time PCR
Arora, 2014	51.6	0-6, 6-15, 15-30 months	< 1 Year	Nov 2011-May 2012	Cross-sectional	Consecutive	Prospectively	Turkey	English	Low risk	Outpatient	Brochialis was defined as a clinical picture of respiratory tract infection with cough, tachypnea, retractions and/or wheezing on auscultation, in accordance with the national recommendations for the diagnosis and management of acute bronchiolitis (McConnochie et al. 2009)	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	Real-time multiplex PCR
Banbajger, 2012	62	17.8 ± 16.6 weeks	< 1 Year	Dec 2009-Mar 2009	Cross-sectional	Consecutive	Prospectively	Israel	English	Low risk	Outpatient	Acute BR was diagnosed clinically in these subjects with upper respiratory tract infection (URTI) with cough and/or rhinorrhea with signs of acute respiratory distress, tachypnea, wheezing, or rales on auscultation	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	PCR
Bakker, 2013	54.2	1-2 months	< 1 Year	Dec 2011-Mar 2012	Cross-sectional	Consecutive	Prospectively	Netherlands	English	Low risk	Outpatient	Brochialis was defined as acute respiratory distress, accompanied by cough, cough, inspiratory crackles and/or wheezing on auscultation	Nonpharyngeal secretion	RSV, HMPV, EV, HAIV, HBoV, HPPV, HCoV, EV	Real-time PCR
Bakker, 2019	59	4:9 (1.4-7.3) mo	< 1 Year	Dec-Mar 2012-2016	Cross-sectional	Consecutive sampling	Prospectively	Netherlands	English	Medium risk of bias	Outpatient	Brochialis was defined as acute respiratory distress accompanied by cough, cough, inspiratory crackles and/or wheezing on auscultation	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	Real-time PCR
Bonati, 2012	61	4.7 ± 0.39 months	< 1 Year	2006-2009 (Nov-Apr)	Cross-sectional	Consecutive	Prospectively	Iran	English	Low risk	Outpatient/Outpatient	Brochialis was defined as acute infection of the lower airways, characterized by increased respiratory effort (tachypnea and/or use of accessory respiratory muscles) and accessory wheezing and/or crackles and/or rales	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	PCR
Calvo, 2010	55	7.6 ± 7.7 months	< 1 Year	Sept 2009-Aug 2008	Cross-sectional	Consecutive	Prospectively	Spain	English	Low risk	Outpatient	Acute bronchiolitis was diagnosed as the first episode of acute lower respiratory distress with previous signs of viral respiratory infection - whether or not the episode associated to respiratory distress or pneumonia in children under 2 years old	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	PCR
Campana, 2016	54.6	Median age 2.1 (1.3-3.0) months	< 1 Year	2006-2014 (Oct-May)	Cross-sectional	Consecutive	Prospectively	Italy	English	Low risk	Outpatient	Acute bronchiolitis was clinically defined as the first episode of acute lower respiratory tract infection in infants less than 12 months, characterized by the acute onset of cough, tachypnea, retractions, and diffuse crackles on chest auscultation	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	PCR
Chen, 2014	67.3	Mean 225 of days 99% CI 204-270 days	< 1 Year	Jan 2009-Dec 2010	Cross-sectional	Consecutive	Prospectively	China	English	Low risk	Outpatient	Acute bronchiolitis was defined as the first episode of cough, rhinorrhea, wheezing, or rales, with chest radiographic findings of over-inflation and peribronchovascular interstitial with or without pulmonary consolidation within 2 days	Nonpharyngeal secretion	HMPV, HBoV	PCR
Davis-Koon, 2018	Unclear/Not reported	2-8 ± 2.4 months 8.1 months (SD 6.7)	< 1 Year	Nov 2004-Feb 2007	Cross-sectional	Consecutive sampling	Retrospectively	South Korea	Non-English	Medium risk of bias	Outpatient	Brochialis (as defined by the American Academy of Pediatrics) of acute respiratory illness with acute combination of rhinorrhea, cough, tachypnea, wheezing, crackles and retractions, and was younger than 2 years	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	Real-time PCR
Davis, 2016	59	1-8 months (SD 3.2)	< 1 Year	2007-2010 (Nov-Mar)	Cross-sectional	Consecutive	Prospectively	USA	English	Low risk	Outpatient	Brochialis (as defined by the American Academy of Pediatrics) of acute respiratory illness with some combination of rhinorrhea, cough, tachypnea, wheezing, crackles and retractions, and was younger than 2 years	Nonpharyngeal secretion	RSV, EV	PCR
Elgharib, 2009	Not reported	Not reported	< 1 Year	Oct 2002-Sep 2005	Cross-sectional	Consecutive	Prospectively	Egypt	English	Medium risk	Outpatient	Not reported	Nonpharyngeal secretion	EV	PCR
Elgharib, 2017	Not reported	1-6.5 months	< 1 Year	Oct 2012-Oct 2016	Cross-sectional	Consecutive	Prospectively	Egypt	English	Low risk	Outpatient	Brochialis (as defined by the American Academy of Pediatrics) of acute respiratory illness with acute combination of rhinorrhea, cough, tachypnea, wheezing, crackles and retractions, and was younger than 2 years	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	Real-time PCR
Hardoon, 2018	60.8	3.60 ± 3.56 months	< 1 Year	Jan 2010-Dec 2012	Cross-sectional	Consecutive	Retrospectively	Qatar	English	Medium risk	Outpatient	The diagnosis of bronchiolitis was based on the definition suggested by the American Academy of pediatrics, (based on diagnosis and assessment of bronchiolitis)	Nonpharyngeal secretion	RSV, EV, HAIV, HBoV, HPPV, HCoV, EV	Real-time PCR
Janji, 2017	67	Not reported	< 1 Year	2010-2011	Cross-sectional	Consecutive	Retrospectively	Qatar	English	Low risk	Outpatient	Acute bronchiolitis defined according to International Classification of Disease (ICD) code 463.1 in the 10th revision of the ICD. Based on a medical diagnosis, an episode of acute bronchiolitis was determined by a combination of clinical signs and symptoms including fever, rhinorrhea, tachypnea, cough, wheezing, crackles, use of accessory muscles and possible chest X-ray findings of hyperinflation of the lung, post-bronchial hyperinflation, collapsed segment or a lobe of the lung and increase intercostal markings	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	Real-time PCR
Jani, 2014	61	8.1 months (SD 6.7)	< 1 Year	2007-2010 (Nov-Mar)	Cross-sectional	Consecutive	Prospectively	Finland	English	Low risk	Outpatient	Brochialis (as defined by the American Academy of Pediatrics) of acute respiratory illness with acute combination of rhinorrhea, cough, tachypnea, wheezing, crackles and retractions, and was younger than 2 years	Nonpharyngeal secretion	HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	PCR
Manbach, 2008	61	Median age of 6.1 months (IQR 3.1 to 10.2)	< 1 Year	Oct 2003-Mar 2006	Cohort	Consecutive	Prospectively	USA	English	Medium risk	Outpatient	The diagnosis of bronchiolitis was confirmed by children younger than 2 years with acute tachypnea, retractions, and abnormal breath sounds who did not meet criteria for a diagnosis of pneumonia or another respiratory diagnosis. As defined by the AAP in its 2000 position statement, children with bronchiolitis typically have "rhinorrhea, tachypnea, wheezing, cough, crackles, use of accessory muscles, and/or nasal flaring" 12	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	Real-time PCR
Manbach, 2016	Not reported	Not reported	< 1 Year	2011-2014 (Nov-Apr)	Cohort	Consecutive	Prospectively	USA	English	Low risk	Outpatient	Brochialis (as defined by the American Academy of Pediatrics) acute respiratory illness with acute combination of rhinorrhea, cough, tachypnea, wheezing, crackles and retractions, and was younger than 2 years	Nonpharyngeal secretion	RSV, EV	PCR
Maldita, 2010	57	2.5 ± 2.1 months	< 1 Year	2006-2007 (Oct-May)	Cross-sectional	Consecutive	Prospectively	Italy	English	Low risk	Outpatient	Brochialis was diagnosed according to the presence of a history of acute respiratory tract infection followed by acute onset of respiratory distress with cough, tachypnea, retractions and/or wheezing on auscultation	Nasal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	PCR
Maldita, 2018	Not reported	Not reported	< 1 Year	2006-2017 (Sep-May)	Cross-sectional	Consecutive	Prospectively	Italy	English	Low risk	Outpatient	Brochialis was defined as a clinical picture of respiratory tract infection with cough, tachypnea, retractions, and/or wheezing on auscultation, in accordance with the national recommendations for the diagnosis and management of acute bronchiolitis (McConnochie et al. 2009)	Nonpharyngeal secretion	RSV	PCR
Miller, 2013	Not reported	Not reported	< 1 Year	2004-2008 (Sep-May)	Cohort	Consecutive	Prospectively	USA	English	Low risk	Outpatient/Outpatient	Brochialis was defined as lower respiratory infection in infants presenting with wheezing, rales, and/or rhinorrhea	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HPPV, HCoV, EV	PCR
Narayanan, 2010	65	Median age was 6 ± 4 months	< 1 Year	Mar 2006-Jul 2007	Cross-sectional	Consecutive	Prospectively	Israel	English	Low risk	Outpatient	Brochialis was defined as the first episode of wheezing associated with signs of an upper respiratory tract infection	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	PCR, RT-PCR, Real-time RT-PCR
Naves, 2020	Unclear/Not reported	Unclear/Not reported	< 1 Year	Unclear/Not reported	Cross-sectional	Consecutive sampling	Prospectively	Italy	English	Medium risk of bias	Outpatient	Brochialis was defined as an acute infection of the lower airway characterized by increased respiratory effort (tachypnea and/or use of accessory respiratory muscles) and accessory wheezing and/or crackles and/or rales	Nonpharyngeal secretion	HBoV, HMPV, HRSV, EV	Classical PCR
Naves, 2020	Unclear/Not reported	Unclear/Not reported	< 1 Year	Unclear/Not reported	Cross-sectional	Consecutive sampling	Prospectively	Italy	English	Medium risk of bias	Outpatient	Brochialis was defined as an acute infection of the lower airway characterized by increased respiratory effort (tachypnea and/or use of accessory respiratory muscles) and accessory wheezing and/or crackles and/or rales	Nonpharyngeal secretion	HBoV, HMPV, HRSV, EV	Classical RT-PCR
Papadopoulos, 2002	61.3	1-3 months	< 1 Year	Oct 1999-Sep 2000	Cross-sectional	Consecutive	Prospectively	Greece	English	Low risk	Outpatient	Brochialis was defined as acute infection of the lower airway characterized by increased respiratory effort (tachypnea and/or use of accessory respiratory muscles) and accessory wheezing and/or crackles and/or rales	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	PCR
Papoff, 2011	66.8	Median (interquartile, IQR) was 6.1 days (1.3-19.4) days	< 1 Year	2006-2009 (Oct-May)	Cross-sectional	Consecutive	Prospectively	Italy	English	Low risk	Outpatient	Brochialis was diagnosed clinically according to the presence of a history of upper respiratory tract infection followed by acute onset of respiratory distress with cough, tachypnea, retractions, and/or wheezing on auscultation, in accordance with the national recommendations for the diagnosis and management of acute bronchiolitis (McConnochie et al. 2009)	Nasal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	PCR
Pereira, 2018	54.1	Median age 2.03 months (range 0.23-11.17)	< 1 Year	2006-2010 (Oct-May)	Cross-sectional	Consecutive	Retrospectively	Italy	English	Low risk	Outpatient	Brochialis was clinically defined as the first episode of acute lower respiratory tract infection, characterized by the acute onset of cough, tachypnea, retractions, and diffuse crackles on chest auscultation in infants younger than 12 months 13	Nonpharyngeal secretion	RSV, EV	PCR
Phalen, 2017	60.8	6.7 (6.3-7.1) months	< 1 Year	Oct 2010-Apr 2011	Cross-sectional	Consecutive	Prospectively	USA	English	Low risk	Outpatient	Brochialis was defined as a physician diagnosis in children less than 24 months of age with wheezing and/or rales, which history of respiratory tract infection with cough, tachypnea, wheezing, crackles and retractions, and was younger than 2 years	Nonpharyngeal secretion	EV	Real-time PCR
Pitlor, 2009	56	Median 7 (1.2-5.0) months	< 1 Year	May 2012-Sep 2012	Cross-sectional	Consecutive	Prospectively	Brazil	Non-English	Medium risk	Outpatient	BA was defined as the first episode of wheezing, associated with signs and symptoms of acute viral infection and/or rhinorrhea	Nonpharyngeal secretion	EV	RT-PCR
Prank, 2018	61.2	Not reported	< 1 Year	May 2014-Oct 2008	Cross-sectional	Consecutive	Retrospectively	Slovenia	English	Medium risk	Outpatient/Outpatient	Patients were identified through a query of the electronic medical record based on bronchiolitis diagnosis (ICD 10 J21.0-21.9)	Nonpharyngeal secretion	RSV, EV, HBoV	RT-PCR
Racati, 2011	Not reported	Not reported	< 1 Year	Sep 2007-Oct 2008	Cross-sectional	Consecutive	Prospectively	Spain	English	Low risk	Outpatient	Patients were identified through a query of the electronic medical record based on bronchiolitis diagnosis (ICD 10 J21.0-21.9)	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	RT-PCR
Racati, 2011	Not reported	Not reported	< 1 Year	Oct 2007-Oct 2008	Cross-sectional	Consecutive	Prospectively	Spain	English	Low risk	Outpatient	Brochialis was diagnosed according to the presence of the first acute respiratory tract infection characterized by respiratory distress (tachypnea, use of accessory muscles), cough, widespread crackles, wheezing or both, associated with signs of viral infection (nasal)	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	RT-PCR, Real-time RT-PCR
Racati, 2014	60.8	41.7 (15.70-51.3) (Median (95% confidence interval) days)	< 1 Year	Jan 2006-Oct 2008	Cross-sectional	Consecutive	Prospectively	Spain	English	Low risk	Outpatient	Brochialis was defined as a physician diagnosis in children less than 24 months of age with wheezing and/or rales, which history of respiratory tract infection with cough, tachypnea, wheezing, crackles and retractions, and was younger than 2 years	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	PCR
Richard, 2008	Not reported	Not reported	< 1 Year	2003-2008 (Sep-Apr)	Cross-sectional	Consecutive	Retrospectively	France	English	Medium risk	Outpatient	Not reported	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	PCR as NASBA
Rodriguez-Acevedo, 2018	60.5	6 (6.0-7.7) months	< 1 Year	Sep 2012-Jan 2013	Cross-sectional	Consecutive	Retrospectively	Mexico	English	Low risk	Outpatient	Acute bronchiolitis was defined as rhinorrhea, cough, tachypnea, wheezing, rales, and increased respiratory effort (e.g., grunting, nasal flaring, and intercostal and/or subcostal retractions), with symptoms of acuity (e.g., increased respiratory rate, retractions, and oxygen saturation < 90% or lower) 25	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	RT-PCR, NASBA
Sabrino Garcia, 2012	53.6	1.6 (1.3-1.9) months	< 1 Year	Dec 2008-Apr 2009	Cross-sectional	Consecutive	Prospectively	Spain	Non-English	Low risk	Outpatient	The diagnosis of bronchiolitis was established according to the McConnochie definition: defined as the first acute episode of respiratory distress with wheezing associated with careful pathology in children under 2 years old	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	RT-PCR
Seem, 2016	Not reported	Not reported	< 1 Year	Sep 2010-Aug 2011	Cross-sectional	Consecutive	Prospectively	Brazil	English	Low risk	Outpatient	Acute bronchiolitis (based on predominant symptoms, with wheezing, crackles, and tachypnea) having been recorded within the first 48 h of hospitalization, and being a ? 75-h history of clinical manifestations of lower respiratory tract infection (viral or respiratory distress)	Nonpharyngeal secretion	RSV, HMPV, EV	Real-time PCR
Seif, 2019	53.9	4 months	< 1 Year	2016-2017	Cross-sectional	Consecutive sampling	Prospectively	Greece	English	Medium risk of bias	Outpatient	Unclear/Not reported	Nonpharyngeal secretion	RSV	Classical RT-PCR
Shi, 2018	52.8	Not reported	< 1 Year	Nov 2007-May 2013	Cross-sectional	Consecutive sampling	Prospectively	South Korea	Non-English	Low risk of bias	Outpatient	Brochialis was defined as acute infection of the lower airway characterized by increased respiratory effort (tachypnea and/or use of accessory respiratory muscles) and accessory wheezing and/or crackles and/or rales	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	Real-time PCR
Tzouvelekis, 2007	Not reported	Not reported	< 1 Year	Apr 2002-Aug 2006	Cross-sectional	Consecutive	Prospectively	Greece	English	Low risk	Outpatient	Brochialis was defined as acute infection of the lower airway characterized by increased respiratory effort (tachypnea and/or use of accessory respiratory muscles) and accessory wheezing and/or crackles and/or rales	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	RT-PCR
Tzouvelekis, 2007	Not reported	Not reported	< 1 Year	Apr 2002-Aug 2006	Cross-sectional	Consecutive	Prospectively	Greece	English	Low risk of bias	Outpatient	Brochialis was defined as acute infection of the lower airway characterized by increased respiratory effort (tachypnea and/or use of accessory respiratory muscles) and accessory wheezing and/or crackles and/or rales	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	Real-time PCR
Uyar, 2014	72.8	1.78 ± 1.53 months	< 1 Year	Jan 2010-Jun 2010	Cross-sectional	Consecutive	Prospectively	Turkey	Non-English	Low risk	Outpatient	Diagnosis of acute bronchiolitis: upper respiratory tract infection, discharge, cough, mild fever, agitation, tachypnea, wheezing, crackles, and/or rales on auscultation, with or without rhinorrhea, wheezing, or rales on auscultation, in accordance with the national recommendations for the diagnosis and management of acute bronchiolitis (McConnochie et al. 2009)	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	Multiple PCR
Vizcarra, 2017	64	2.1 months (SD 1.4)	< 1 Year	2011-2013	Cross-sectional	Consecutive	Prospectively	Brazil	English	Medium risk	Outpatient	Acute bronchiolitis was defined as acute respiratory tract infection characterized by increased respiratory effort (tachypnea and/or use of accessory respiratory muscles) and accessory wheezing and/or crackles and/or rales	Nasal secretion	RSV	Real-time PCR
Wang, 2015	66.4	Not reported	< 1 Year	2010-Dec 2013	Cross-sectional	Consecutive	Prospectively	China	English	Low risk	Outpatient	The bronchiolitis was defined as the first wheezing event, beginning more than 1 week before hospital admission	Nonpharyngeal secretion	RSV	Real-time PCR
Wittmann, 2018	Unclear/Not reported	Unclear/Not reported	< 1 Year	2006-2014	Cross-sectional	Consecutive sampling	Prospectively	Brazil	English	Medium risk of bias	Outpatient	The bronchiolitis was defined based on the guidelines described by Zhu Feng, Practical Pediatrics, 3rd Edition (13)	Nonpharyngeal secretion	RSV, HMPV, Influenza, EV, HAIV, HBoV, HPPV, HCoV, EV	Real-time RT-PCR
Xapapichit, 2004	Not reported	Not reported	< 1 Year	Oct 1999-Sep 2000	Cross-sectional	Consecutive	Prospectively	Greece	English	Low risk	Outpatient	Brochialis was defined as acute infection of the lower airway characterized by increased respiratory effort (tachypnea and/or use of accessory respiratory muscles) and accessory wheezing and/or crackles and/or rales	Nonpharyngeal secretion	HMPV	PCR
Yoon, 2014	Unclear/Not reported	Unclear/Not reported	< 1 Year	Jan 2014 (Winter)	Cross-sectional	Consecutive sampling	Prospectively	China	Non-English	Medium risk of bias	Unclear/Not reported	Unclear/Not reported	Nonpharyngeal secretion	HBoV, HRSV	Classical PCR
Zhou, 2015	Not reported	Not reported	< 1 Year	2012-2014 (Winter)	Cross-sectional	Consecutive	Prospectively	China	Non-English	Medium risk of bias	Unclear/Not reported	Unclear/Not reported	Nonpharyngeal secretion	RSV	Nonpharyngeal secretion

S6 Table. Global prevalence and sensitivity analyses of respiratory viral infections in children < 2 years with bronchiolitis

	Prevalence [95% CI]	95% Prediction interval	N Studies	N Cases	H [95% CI]	I ² [95% CI]	P-Value Heterogeneity	P-Value Egger test
HRSV								
Overall	59.2 [54.7-63.6]	[29.1-85.9]	45	15351	5.5 [5.1-6]	96.8 [96.2-97.2]	< 0.001	0.415
< 1 Year	62.3 [55.7-68.6]	[32.4-87.8]	18	6779	5.4 [4.7-6.1]	96.5 [95.5-97.3]	< 0.001	0.878
Hospitalized	60.6 [55.9-65.2]	[32.8-85.2]	34	12867	5.3 [4.8-5.8]	96.4 [95.7-97]	< 0.001	0.601
Bronchiolitis definition given	60.4 [56-64.8]	[32.4-85.2]	40	14456	5.3 [4.8-5.7]	96.4 [95.7-97]	< 0.001	0.473
Cross sectional design	57.2 [52.3-62]	[27.2-84.5]	39	12992	5.4 [5-5.9]	96.6 [96-97.2]	< 0.001	0.395
Low risk of bias	59.4 [54.1-64.5]	[30.4-85.2]	30	11024	5.4 [4.9-5.9]	96.5 [95.8-97.2]	< 0.001	0.325
RV								
Overall	19.3 [16.7-22]	[6.3-37]	36	12967	3.7 [3.3-4.2]	92.8 [90.9-94.2]	< 0.001	0.318
< 1 Year	16.9 [13.4-20.7]	[4.8-34]	15	5382	3.4 [2.8-4.1]	91.5 [87.6-94.1]	< 0.001	0.856
Hospitalized	18 [15.1-21.1]	[5-36.4]	28	11159	4 [3.5-4.5]	93.8 [92-95.1]	< 0.001	0.142
Bronchiolitis definition given	19.2 [16.6-22]	[6.2-37.2]	35	12787	3.8 [3.4-4.2]	93 [91.2-94.4]	< 0.001	0.315
Cross sectional design	19.9 [16.9-23.2]	[5.9-39.4]	30	10833	4 [3.5-4.5]	93.6 [91.9-95]	< 0.001	0.315
Low risk of bias	21 [18-24.2]	[8-37.9]	25	9414	3.5 [3-4]	91.6 [88.9-93.7]	< 0.001	0.304
HBoV								
Overall	8.2 [5.6-11.2]	[0-27.3]	24	8706	4.7 [4.1-5.3]	95.4 [94.1-96.4]	< 0.001	0.748
< 1 Year	8 [2.4-16.6]	[0-49]	8	3104	7.3 [6.2-8.6]	98.1 [97.4-98.7]	< 0.001	0.864

	Prevalence [95% CI]	95% Prediction interval	N Studies	N Cases	H [95% CI]	I2 [95% CI]	P-Value Heterogeneity	P-Value Egger test
Hospitalized	8 [5-11.6]	[0-28.6]	18	7335	5.2 [4.5-5.9]	96.2 [95.1-97.1]	< 0.001	0.853
Bronchiolitis definition given	8.2 [5.5-11.3]	[0-27.8]	23	8310	4.8 [4.2-5.4]	95.6 [94.4-96.6]	< 0.001	0.753
Cross sectional design	8.3 [5.6-11.4]	[0-27.6]	23	8572	4.8 [4.2-5.4]	95.6 [94.4-96.6]	< 0.001	0.777
Low risk of bias	9.5 [6.5-13.1]	[0.3-28.2]	17	5578	4.1 [3.5-4.8]	94 [91.8-95.6]	< 0.001	0.331
HAdV								
Overall	6.1 [4.4-8]	[0.2-18.1]	26	6734	3 [2.6-3.5]	88.9 [85-91.8]	< 0.001	0.085
< 1 Year	6.7 [3.6-10.6]	[0-23.1]	7	1938	3 [2.2-4]	88.6 [78.9-93.8]	< 0.001	0.538
Hospitalized	6.1 [4.2-8.4]	[0.1-18.9]	20	5963	3.3 [2.8-3.9]	90.6 [87-93.3]	< 0.001	0.121
Bronchiolitis definition given	6.2 [4.4-8.2]	[0.2-18.2]	24	6386	3 [2.6-3.5]	89 [84.9-92]	< 0.001	0.097
Cross sectional design	6.4 [4.5-8.6]	[0.2-19.2]	23	6112	3.1 [2.6-3.6]	89.5 [85.6-92.4]	< 0.001	0.149
Low risk of bias	6.4 [4.2-8.9]	[0.1-20]	18	4632	3.1 [2.6-3.7]	89.7 [85.2-92.8]	< 0.001	0.052
HPIV								
Overall	5.4 [3.8-7.3]	[0-17.9]	28	7933	3.3 [2.9-3.8]	91 [88.1-93.2]	< 0.001	0.932
< 1 Year	3.1 [1.9-4.6]	[0.1-9.3]	10	3185	2.1 [1.6-2.9]	78.1 [60.1-88]	< 0.001	0.531
Hospitalized	5 [3.3-6.9]	[0-16.7]	21	6707	3.4 [2.9-3.9]	91.1 [87.8-93.5]	< 0.001	0.238
Bronchiolitis definition given	5 [3.4-6.8]	[0-16.7]	26	7585	3.3 [2.8-3.8]	90.6 [87.4-92.9]	< 0.001	0.682
Cross sectional design	5.3 [3.6-7.2]	[0-17.2]	24	6856	3.2 [2.8-3.7]	90.3 [86.8-92.8]	< 0.001	0.528

	Prevalence [95% CI]	95% Prediction interval	N Studies	N Cases	H [95% CI]	I2 [95% CI]	P-Value Heterogeneity	P-Value Egger test
Low risk of bias	5 [3.1-7.2]	[0-18]	20	5831	3.4 [2.9-4]	91.5 [88.3-93.9]	< 0.001	0.983
HMPV								
Overall	5.4 [4.4-6.4]	[1.4-11.5]	32	9908	2.1 [1.8-2.5]	76.9 [67.7-83.5]	< 0.001	0.043
< 1 Year	3.4 [2.4-4.7]	[0.5-8.4]	12	3936	1.9 [1.4-2.5]	71.4 [48.6-84.1]	< 0.001	0.633
Hospitalized	5.1 [4.2-6.1]	[1.9-9.7]	26	8850	1.8 [1.5-2.2]	68.8 [53.2-79.1]	< 0.001	0.238
Bronchiolitis definition given	5.4 [4.4-6.4]	[1.4-11.5]	32	9908	2.1 [1.8-2.5]	76.9 [67.7-83.5]	< 0.001	0.043
Cross sectional design	5.6 [4.6-6.7]	[1.9-11.1]	28	8831	1.9 [1.6-2.3]	72.7 [60.3-81.2]	< 0.001	0.04
Low risk of bias	5.7 [4.5-7]	[1.3-12.8]	26	8034	2.2 [1.9-2.7]	79.6 [70.8-85.8]	< 0.001	0.07
Influenza								
Overall	3.2 [2.2-4.3]	[0-10]	24	6571	2.4 [2-2.8]	82.1 [74.3-87.5]	< 0.001	0.032
< 1 Year	1.6 [0.8-2.6]	[0-5.2]	8	2694	1.7 [1.2-2.5]	65.4 [26.3-83.7]	0.005	0.422
Hospitalized	2.6 [1.8-3.6]	[0.1-7.8]	19	5734	2.1 [1.7-2.6]	77.4 [65.1-85.4]	< 0.001	0.407
Bronchiolitis definition given	3.2 [2.1-4.4]	[0-10.2]	23	6391	2.4 [2-2.9]	82.8 [75.3-88.1]	< 0.001	0.037
Cross sectional design	3 [2-4.3]	[0-10.1]	21	5764	2.4 [2-2.9]	82.8 [74.8-88.3]	< 0.001	0.083
Low risk of bias	3.2 [2.1-4.6]	[0-10.6]	19	5561	2.5 [2.1-3.1]	84.2 [76.7-89.4]	< 0.001	0.08
HCoV								
Overall	2.9 [2-4]	[0-9.9]	27	7431	2.5 [2.1-2.9]	83.5 [76.9-88.1]	< 0.001	0.918
< 1 Year	2.6 [1-4.8]	[0-13.3]	10	3056	3.1 [2.4-4]	89.7 [83.2-93.7]	< 0.001	0.744

	Prevalence [95% CI]	95% Prediction interval	N Studies	N Cases	H [95% CI]	I2 [95% CI]	P-Value Heterogeneity	P-Value Egger test
Hospitalized	2.6 [1.6-3.8]	[0-9.4]	22	6435	2.5 [2.1-3]	84 [76.9-88.9]	< 0.001	0.556
Bronchiolitis definition given	2.9 [2-4.1]	[0-10]	26	7313	2.5 [2.1-3]	84.1 [77.7-88.6]	< 0.001	0.931
Cross sectional design	2.6 [1.7-3.7]	[0-8.8]	23	6354	2.3 [1.9-2.8]	81.1 [72.5-87]	< 0.001	0.744
Low risk of bias	2.8 [1.8-4]	[0-9.4]	20	5559	2.3 [1.9-2.8]	81.5 [72.3-87.6]	< 0.001	0.701
EV								
Overall	2.9 [1.6-4.5]	[0-11.4]	15	4202	2.7 [2.2-3.3]	86.1 [78.6-90.9]	< 0.001	0.886
< 1 Year	2.2 [1.4-3]	[0.7-4.3]	4	1303	1 [1-2.3]	0 [0-80.5]	0.502	0.292
Hospitalized	2.2 [1-3.6]	[0-9.1]	11	3700	2.6 [2-3.3]	84.7 [74.3-90.9]	< 0.001	0.115
Bronchiolitis definition given	2.8 [1.4-4.6]	[0-11.7]	14	4022	2.8 [2.2-3.5]	87 [79.9-91.6]	< 0.001	0.849
Cross sectional design	2.9 [1.5-4.7]	[0-12]	14	3984	2.8 [2.2-3.5]	87 [79.9-91.6]	< 0.001	0.911
Low risk of bias	3.4 [1.7-5.6]	[0-13.5]	11	3386	2.8 [2.2-3.6]	87.7 [79.9-92.5]	< 0.001	0.863

CI: confidence interval; RV: Rhinovirus; HCoV: Human Coronavirus; HPIV: Human Parainfluenzavirus; HMPV: Human Metapneumovirus; HRSV: Human Respiratory Syncytial Virus; HAdV: Human Adenovirus; HBoV: Human Bocavirus; EV: Enterovirus; NA: not applicable.

S7 Table. Subgroup prevalence of respiratory viral infections in children with acute bronchiolitis

	Prevalence [95% CI]	95% Prediction interval	H [95% CI]	N Studies	N Cases	I2 [95% CI]	P-Value Heterogeneity	P-Value Egger test	P-value subgroup difference
HRSV									
Study period									0.304
Continuous study period	57.3 [51.6-62.9]	[26.1-85.6]	4.9 [4.4-5.4]	30	7454	95.8 [94.9-96.6]	< 0.001	0.647	
Interrupted time series study	62.4 [54.3-70.2]	[28.7-90.5]	6.6 [5.8-7.5]	14	7073	97.7 [97-98.2]	< 0.001	0.622	
WHO Region									< 0.001
America	64 [58.2-69.6]	[42.8-82.7]	3.5 [2.8-4.4]	10	4731	92 [87.4-94.9]	< 0.001	0.104	
Eastern Mediterranean	46.9 [40.2-53.7]	[0-100]	2.2 [1.3-4]	3	1240	80 [36.8-93.7]	0.007	0.386	
Europe	59 [52.9-64.9]	[27.4-86.9]	5.3 [4.7-5.9]	26	7636	96.4 [95.6-97.1]	< 0.001	0.815	
Northern America	82.6 [77.8-86.9]	NA	NA	1	270	NA	1	NA	
South-East Asia	64.7 [57.3-71.7]	NA	NA	1	170	NA	1	NA	
Western Pacific	51.3 [32.1-70.3]	[0-100]	6.1 [4.6-8.1]	4	1304	97.3 [95.3-98.5]	< 0.001	0.705	
Sample type									< 0.001
Nasal secretions	50 [36.5-63.5]	[1.6-98.4]	4 [2.8-5.8]	4	902	93.9 [87.4-97]	< 0.001	0.116	
Nasopharyngeal secretions	61 [56.8-65.2]	[34-84.9]	5 [4.6-5.5]	40	14053	96 [95.2-96.6]	< 0.001	0.465	
Throat secretions	24.5 [20.4-28.9]	NA	NA	1	396	NA	1	NA	
RV									
Study period									0.391
Continuous study period	20.4 [16.9-24]	[6.3-39.6]	3.3 [2.8-3.8]	24	6199	90.8 [87.7-93.2]	< 0.001	0.314	
Interrupted time series study	18 [13.7-22.7]	[4.5-37.8]	4.2 [3.5-5.1]	11	5944	94.4 [91.8-96.2]	< 0.001	0.178	
WHO Region									< 0.001
America	17.8 [13.6-22.4]	[5.5-34.9]	3.2 [2.5-4.2]	9	4570	90.5 [84.2-94.3]	< 0.001	0.187	
Eastern Mediterranean	18.8 [8.3-32.3]	NA	4.9 [2.9-8.3]	2	1072	95.9 [88.4-98.6]	< 0.001	NA	

	Prevalence [95% CI]	95% Prediction interval	H [95% CI]	N Studies	N Cases	I2 [95% CI]	P-Value Heterogeneity	P-Value Egger test	P-value subgroup difference
Europe	19.3 [15.9-23]	[5.1-39.5]	3.6 [3.1-4.1]	24	6557	92.2 [89.7-94.1]	< 0.001	0.905	
Western Pacific	33.5 [30.2-36.8]	NA	NA	1	768	NA	1	NA	
Sample type									0.243
Nasal secretions	12.7 [3.9-25.4]	[0-100]	4.7 [3.1-6.9]	3	808	95.4 [89.9-97.9]	< 0.001	0.762	
Nasopharyngeal secretions	20 [17.3-22.8]	[7.2-37]	3.6 [3.2-4]	33	12159	92.2 [90.1-93.9]	< 0.001	0.441	
HBoV									
Study period									0.09
Continuous study period	9.4 [6.4-12.9]	[0.1-29.1]	4.5 [4-5.2]	19	6897	95.2 [93.6-96.3]	< 0.001	0.497	
Interrupted time series study	5.1 [2.2-9.1]	[0-30.4]	2.4 [1.5-3.9]	4	985	82.9 [56.4-93.3]	0.001	0.386	
WHO Region									< 0.001
America	4.7 [0-15.2]	[0-100]	3.8 [2.4-5.9]	3	525	93.1 [83.1-97.2]	< 0.001	0.11	
Eastern Mediterranean	4 [2.9-5.3]	NA	1	2	1072	0	0.913	NA	
Europe	9 [5.4-13.5]	[0-33.4]	4.9 [4.3-5.7]	16	4947	95.9 [94.5-96.9]	< 0.001	0.884	
Western Pacific	11.6 [10.3-13]	[4.3-21.7]	1 [1-2.9]	3	2162	0 [0-88.3]	0.411	0.47	
Sample type									0.545
Nasal secretions	6.6 [2.7-12]	[0-97]	2.6 [1.5-4.5]	3	808	85.6 [57.9-95.1]	0.001	0.344	
Nasopharyngeal secretions	8.4 [5.4-12]	[0-29.4]	5 [4.4-5.7]	20	7502	96 [94.9-96.9]	< 0.001	0.784	
Throat secretions	9.8 [7.1-13]	NA	NA	1	396	NA	1	NA	
HAdV									
Study period									0.081
Continuous study period	6.6 [4.7-8.8]	[0.3-18.8]	3 [2.5-3.5]	22	5786	88.6 [84.1-91.8]	< 0.001	0.081	
Interrupted time series study	3.7 [1.6-6.5]	[0-20.2]	1.9 [1.1-3.2]	4	948	72 [20.7-90.1]	0.013	0.501	
WHO Region									< 0.001
America	1.5 [0.4-3.2]	[0-31]	1.2 [1-3.6]	3	525	24.9 [0-92.2]	0.264	0.454	


	Prevalence [95% CI]	95% Prediction interval	H [95% CI]	N Studies	N Cases	I2 [95% CI]	P-Value Heterogeneity	P-Value Egger test	P-value subgroup difference
Eastern Mediterranean	6.9 [4.6-9.6]	[0-51.6]	1.6 [1-3]	3	1240	61.8 [0-89.1]	0.073	0.177	
Europe	6.3 [4.5-8.4]	[0.7-16.4]	2.3 [1.9-2.9]	18	3931	81.8 [72.2-88]	< 0.001	0.543	
Northern America	5.9 [3.4-9.1]	NA	NA	1	270	NA	1	NA	
Western Pacific	18.1 [15.5-20.9]	NA	NA	1	768	NA	1	NA	
Sample type									0.532
Nasal secretions	7.3 [4.6-10.4]	NA	NA	1	316	NA	1	NA	
Nasopharyngeal secretions	6 [4.2-8.1]	[0.1-18.5]	3.1 [2.6-3.6]	25	6418	89.3 [85.5-92.1]	< 0.001	0.092	
HPIV									
Study period									0.005
Continuous study period	6.7 [4.6-9.1]	[0.1-20.5]	3.3 [2.8-3.9]	20	5687	91 [87.5-93.5]	< 0.001	0.943	
Interrupted time series study	2.8 [1.4-4.6]	[0-10.3]	2.2 [1.6-3.1]	8	2246	79.3 [59.6-89.4]	< 0.001	0.622	
WHO Region									< 0.001
America	6 [0.8-15]	[0-67.2]	4.4 [3.1-6.2]	4	980	94.8 [89.8-97.4]	< 0.001	0.166	
Eastern Mediterranean	11.6 [6.8-17.4]	[0-95.4]	2.7 [1.6-4.6]	3	1240	86.4 [60.6-95.3]	0.001	0.424	
Europe	3.9 [2.7-5.3]	[0.3-10.8]	2.1 [1.7-2.7]	19	4675	78.3 [66.7-85.9]	< 0.001	0.283	
Northern America	8.1 [5.2-11.7]	NA	NA	1	270	NA	1	NA	
Western Pacific	13.7 [11.3-16.2]	NA	NA	1	768	NA	1	NA	
Sample type									0.086
Nasal secretions	2.8 [0.8-5.9]	[0-76.1]	2.1 [1.2-3.8]	3	808	78.1 [29.5-93.2]	0.01	0.718	
Nasopharyngeal secretions	5.8 [4-7.9]	[0-19]	3.4 [2.9-3.9]	25	7125	91.4 [88.5-93.5]	< 0.001	0.969	
HMPV									
Study period									0.005
Continuous study period	6.3 [5.2-7.4]	[2.6-11.2]	1.7 [1.3-2.1]	24	7018	64.3 [44.8-76.9]	< 0.001	0.012	
Interrupted time series study	3.1 [1.5-5.1]	[0-11.8]	2.3 [1.6-3.3]	7	2066	81.4 [62.6-90.8]	< 0.001	0.735	

	Prevalence [95% CI]	95% Prediction interval	H [95% CI]	N Studies	N Cases	I2 [95% CI]	P-Value Heterogeneity	P-Value Egger test	P-value subgroup difference
WHO Region									0.443
America	5.4 [1.6-11.1]	[0-33.5]	3 [2.1-4.4]	5	1036	89 [77-94.7]	< 0.001	0.117	
Eastern Mediterranean	6.2 [4-8.9]	NA	NA	1	369	NA	1	NA	
Europe	5.7 [4.4-7.2]	[1.2-12.8]	2 [1.7-2.5]	21	5355	76.1 [63.6-84.3]	< 0.001	0.017	
Northern America	3.3 [1.5-5.9]	NA	NA	1	270	NA	1	NA	
South-East Asia	3.5 [1.2-6.9]	NA	NA	1	170	NA	1	NA	
Western Pacific	5.5 [4.5-6.7]	[0-20.3]	1.3 [1-2.3]	3	2708	38.6 [0-80.8]	0.196	0.692	
Sample type									0.198
Nasal secretions	3.7 [1.4-7]	[0-25.9]	2.8 [1.8-4.4]	4	1750	87.6 [70.5-94.8]	< 0.001	0.655	
Nasopharyngeal secretions	5.7 [4.6-6.8]	[1.6-11.8]	2 [1.7-2.4]	28	8158	74.7 [63.5-82.5]	< 0.001	0.017	
Influenza									
Study period									0.014
Continuous study period	4 [2.6-5.8]	[0-12.8]	2.5 [2-3.1]	16	4325	84.4 [76.1-89.9]	< 0.001	0.055	
Interrupted time series study	1.9 [1-3]	[0-5.9]	1.6 [1.1-2.4]	8	2246	62.8 [20-82.7]	0.009	0.313	
WHO Region									0.058
America	2.8 [0.5-6.4]	[0-28]	2.5 [1.6-4]	4	980	83.9 [59.4-93.6]	< 0.001	0.426	
Eastern Mediterranean	1.1 [0.2-2.5]	NA	NA	1	369	NA	1	NA	
Europe	3.5 [2.2-5]	[0-11.7]	2.4 [2-3]	18	4454	83.3 [74.8-88.9]	< 0.001	0.034	
Western Pacific	3.3 [2.1-4.6]	NA	NA	1	768	NA	1	NA	
Sample type									0.677
Nasal secretions	2.2 [0-9.2]	[0-100]	4.5 [3-6.7]	3	808	95 [88.8-97.8]	< 0.001	0.74	
Nasopharyngeal secretions	3.2 [2.3-4.4]	[0.2-9.1]	2.1 [1.7-2.6]	21	5763	77.3 [65.7-85]	< 0.001	0.006	
HCoV									
Study period									0.589
Continuous study period	3.1 [2-4.4]	[0-9.8]	2.3 [1.9-2.8]	20	5365	80.9 [71.3-87.2]	< 0.001	0.789	


	Prevalence [95% CI]	95% Prediction interval	H [95% CI]	N Studies	N Cases	I2 [95% CI]	P-Value Heterogeneity	P-Value Egger test	P-value subgroup difference
Interrupted time series study	2.5 [0.8-5.1]	[0-14.6]	3 [2.2-4]	7	2066	88.7 [79.2-93.9]	< 0.001	0.717	
WHO Region									< 0.001
America	1.5 [0.8-2.4]	[0.2-3.7]	1 [1-2]	4	980	0 [0-75.5]	0.598	0.625	
Eastern Mediterranean	4.2 [1.4-8.4]	NA	2.7 [1.4-5.4]	2	1072	86.5 [46.7-96.6]	0.006	NA	
Europe	2.6 [1.5-4.1]	[0-10.4]	2.4 [2-3]	18	4223	83 [74.3-88.8]	< 0.001	0.639	
Northern America	10.7 [7.3-14.7]	NA	NA	1	270	NA	1	NA	
Western Pacific	4.4 [2.4-7]	NA	1.3 NA	2	886	37.7 NA	0.205	NA	
Sample type									0.071
Nasal secretions	1.1 [0-3.3]	[0-70]	2.1 [1.2-3.8]	3	808	77.7 [27.9-93.1]	0.011	0.79	
Nasopharyngeal secretions	3.2 [2.2-4.4]	[0-10.3]	2.4 [2-2.9]	24	6623	82.8 [75.5-88]	< 0.001	0.969	
EV									
Study period									0.466
Continuous study period	2.6 [1-4.7]	[0-13.3]	3.1 [2.4-3.9]	11	3254	89.4 [83-93.4]	< 0.001	0.716	
Interrupted time series study	3.6 [2.1-5.5]	[0-12.1]	1.3 [1-2.3]	4	948	44.1 [0-81.3]	0.147	0.304	
WHO Region									< 0.001
America	20.8 [12.4-30.6]	NA	NA	1	77	NA	1	NA	
Eastern Mediterranean	1.6 [0.5-3.2]	NA	NA	1	369	NA	1	NA	
Europe	2 [1.2-2.9]	[0.2-5.2]	1.5 [1.1-2.1]	12	2988	55.3 [14.5-76.6]	0.01	0.632	
Western Pacific	7.8 [6-9.8]	NA	NA	1	768	NA	1	NA	
Sample type									NA
Nasopharyngeal secretions	2.9 [1.6-4.5]	[0-11.4]	2.7 [2.2-3.3]	15	4202	86.1 [78.6-90.9]	< 0.001	0.886	

CI: confidence interval; RV: Rhinovirus; HCoV: Human Coronavirus; HPIV: Human Parainfluenzavirus; HMPV: Human Metapneumovirus; HRSV: Human Respiratory Syncytial Virus; HAdV: Human Adenovirus; HBoV: Human Bocavirus; EV: Enterovirus; NA: not applicable.


S1 Fig. Global prevalence of Respiratory Viruses in children < 2 years with bronchiolitis




S2 Fig. Codetection rate of viral infections among children < 2 years with bronchiolitis




S4 Fig. Funnel plot for publication for RV in people with bronchiolitis




S6 Fig. Funnel plot for publication for HAdV in people with bronchiolitis




S8 Fig. Funnel plot for publication for HPIV in people with bronchiolitis



S9 Fig. Funnel plot for publication for Influenza in people with bronchiolitis



S10 Fig. Funnel plot for publication for EV in people with bronchiolitis



S11 Fig. Funnel plot for publication for HCoV in people with bronchiolitis

